Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Australia
ORYGEN Research Centre, Department of Psychiatry, University of Melbourne, Australia
Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Department of Psychology, Australian Catholic University, Australia
Department of Psychology, University of Melbourne, Australia
Research Centre, Department of Psychiatry, University of Melbourne, Australia
Department of Psychology, University of Melbourne, Australia
ORYGEN Research Centre, Department of Psychiatry, University of Melbourne, Australia
Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Australia
Correspondence: Dr Stephen Wood, Melbourne Neuropsychiatry Centre, c/o National Neuroscience Facility, 161 Barry Street, Carlton South, VIC 3053 Australia. tel: +61 3 8344 1877; fax: +61 3 9348 0469; email: sjwood{at}unimelb.edu.au
Declaration of interest None. Funding detailed in Acknowledgements.
|
|
|---|
Aims To investigate whether cognitive function declined over the transition to psychosis in a group of ultra-high risk individuals.
Method Participants consisted of two groups: controls (n=17) and individuals at ultra-high risk for development of psychosis (n=16). Seven of the latter group later developed psychosis. Neuropsychological testing was conducted at baseline and again after at least a 12-month interval.
Results Both the Visual Reproduction sub-test of the Wechsler Memory Scale-Revised and Trail-Making Test B showed a decline over the follow-up period that was specific to the group who became psychotic. In addition, both high-risk groups showed a decline in digit span performance. No other task showed significant change over time.
Conclusions These preliminary data suggest that as psychosis develops there may be a specific decline in visual memory and attentional set-shifting, reflecting impairments in efficient organisation of visual stimuli. This may be caused by either the illness itself or treatment with antipsychotic medication.
|
|
|---|
|
|
|---|
The criteria for identification of the ultra-high risk group have been previously described (Yung et al, 2003, 2004); briefly, participants met the criteria for one or more of the following categories at intake: trait plus state risk factors; attenuated psychotic symptoms; or brief limited intermittent psychotic symptoms (BLIPS). The criteria met by the participants at ultra-high risk were as follows: trait plus state (n=3), attenuated symptoms (n=8), BLIPS (n=2), trait plus state and attenuated symptoms (n=1), attenuated symptoms and BLIPS (n=1), and all three categories (n=1). All participants at ultra-high risk were between the ages of 14 and 29 years at baseline, had not experienced a previous psychotic episode (treated or untreated), and reported English as the preferred language. In order to identify the onset of acute levels of psychosis in the ultra-high risk group, operationalised criteria for the onset of psychosis have been defined (Yung et al, 2003, 2004). Individuals at ultra-high risk were divided into two subgroups, depending on psychotic status at the follow-up assessment: ultra-high risk with psychosis (n=7) and ultra-high risk with no psychosis (n=9).
The psychotic diagnoses in the ultra-high risk with psychosis group at follow-up – using the Diagnostic and Statistical Manual of Mental Disorders (DSM–IV; American Psychiatric Association, 1994) were schizophrenia and schizophreniform psychosis (n=4), brief psychotic disorder (n= 1), bipolar disorder with psychotic features (n=1), and psychotic disorder not otherwise specified (n=1). The majority of the ultra-high risk with no psychosis group had no current axis I diagnosis at follow-up (n=5), while the remaining 4 participants were diagnosed with dysthymia (n=1), obsessive–compulsive disorder (n=1), major depressive disorder (n=1), and generalised anxiety disorder (n=1). One of the participants from the ultra-high risk with no psychosis group received antipsychotic treatment (2 mg risperidone) following the baseline assessment as part of an intervention study exploring the effects of risperidone and psychotherapy on rate of transition to psychosis (McGorry et al, 2002). No other participant from this group took antipsychotic medication. All individuals from the ultra-high risk with psychosis group were prescribed antipsychotics after transition to frank psychosis; however, data concerning the type and dose were unavailable for 3 patients. Of the remaining 4, 2 were no longer taking medication at the time of reassessment, 1 was receiving risperidone and 1 chlorpromazine.
Participants were excluded from the study if they had documented neurological disorder; past history of head injury with loss of consciousness; impaired thyroid function; steroid use or DSM–IV diagnosis of alcohol dependence; estimated premorbid IQ below 70 (i.e. intellectual disability); or for healthy control participants, a personal history of axis I psychiatric illness or documented family history of psychotic illness. Written informed consent from the participants was obtained in accordance with the local research and ethics committee guidelines.
Measures
Premorbid IQ
The National Adult Reading Test (NART;
Nelson & Willison, 1991)
provided an estimate of premorbid intellectual ability. Australian norms
adjusted for educational level (Willshire
et al, 1991) were used to calculate subject scores.
Current IQ
Four subtests of the Wechsler Adult Intelligence Scale – Revised
(WAIS–R, Wechsler, 1981)
were administered in order to calculate the Kaufman 4-test short-form IQ score
(i.e. arithmetic, similarities, picture completion and digit symbol)
(Kaufman, 1990). In addition,
the information, digit span and block design sub-tests were administered.
Attention and executive functioning
The Controlled Oral Word Association Test (COWAT,
Benton & Hamsher, 1983)
provided a measure of verbal fluency, and the Trail-Making Test parts A and B
(Adjutant Generals Office,
1944) assessed visuomotor speed and task-switching ability.
Learning and memory
Sub-tests (logical memory I, paired associates I and visual reproduction I)
from the Wechsler Memory Scale – Revised (WMS–R;
Wechsler, 1987) provided
measures of new verbal learning and of visual and verbal memory function. The
Rey Auditory Verbal Learning Test (RAVLT,
Rey, 1941) modified to three
trials was used to assess new verbal learning capacity and delayed recall.
Fully qualified neuropsychologists or clinical psychologists conducted all research assessments at baseline and at follow-up. Owing to time constraints or compliance problems, not all participants completed all tests at both time points.
Statistical analysis
All data were analysed using SPSS for Mac, version 11. Demographic
variables were compared using
2 (male/female ratio), one-way
analysis of variance (ANOVA; age, NART IQ, time between assessments) or
t-tests (Brief Psychiatric Rating Scale, Schedule for the Assessment
of Negative Symptoms). A series of two-way repeated measures ANOVAs was
conducted to compare change in neuropsychological test scores over time.
Because group effects have already been reported in a much larger sample
(Brewer et al, 2005),
only time and timexgroup effects are reported here. Age-scaled scores or
age-appropriate percentile scores were used where available to obviate the
need for age covarying. However, these were unavailable for certain tests, so
repeated measures ANCOVA was used instead (see below for details).
|
|
|---|
|
View this table: [in a new window] | Table 1 Demographic details for all groups |
Global cognitive function
Baseline and follow-up data for current IQ and the WAIS–R sub-tests
are shown in Table 2. There was
no significant effect of time and no significant timexgroup interaction
for current IQ. Examination of the WAIS–R sub-tests revealed no
significant main effect of time or timexgroup interaction for
information, arithmetic, similarities, picture completion or digit symbol. A
significant effect of time was found for block design (all groups improved at
follow-up), and a significant timexgroup interaction was found for digit
span. Post-hoc tests revealed that only the control group showed a significant
improvement over time (P=0.045), while the two ultra-high risk groups
showed no significant change (P=0.253 and P=0.347
respectively).
|
View this table: [in a new window] | Table 2 Neuropsychological test scores at baseline and follow-up for the three groups* |
Memory
Baseline and follow-up data for the WMS–R sub-tests and the RAVLT are
shown in Table 2. No main
effects of time or time x group interactions were found for the logical
memory, digits forward or the digits backward sub-tests from the WMS–R.
However, there was a significant time x group interaction for the visual
reproduction sub-test. Inspection of the data showed that although the
ultra-high risk with no psychosis group improved markedly over the follow-up
interval, the ultra-high risk with psychosis group showed a decline in
function (Fig. 1).
![]() View larger version (9K): [in a new window] [as a PowerPoint slide] |
Fig. 1 Change in visual reproduction percentile for the three groups (left,
control; right, UHR-P and UHR-NP).
|
Executive function
Baseline and follow-up data for the COWAT and parts A and B of the
Trail-Making Test are shown in Table
2. For both tests, age was covaried as age-appropriate percentiles
were unavailable. No main effect of time or timexgroup interaction was
found for COWAT or for Trail-Making Test A. However, a significant
timexgroup interaction effect was found for Trail-Making Test B, which
was due to a large decline in the performance of the ultra-high risk with
psychosis group. Both the ultra-high risk with no psychosis and the Control
group showed slight improvements over the follow-up
(Fig. 2).
![]() View larger version (8K): [in a new window] [as a PowerPoint slide] |
Fig. 2 Change in Trails B for the three groups (left, controls; right, UHR-P and
UHR-NP).
|
|
|
|---|
These findings contrast with longitudinal studies of cognition in first-episode schizophrenia, which have consistently found no decline in performance over the years following illness onset (Hoff et al, 1999, 2005; Addington et al, 2005). Furthermore, a longitudinal study of cognition in a genetically at-risk group (the Edinburgh High Risk Study, Whyte et al, 2006) also found no specific decline over time in those who developed schizophrenia. Some evidence from cohort studies suggests that general cognitive decline occurs very early in the trajectory of illness, perhaps between late childhood and adolescence (Reichenberg et al, 2005). These differences with the current study are likely to be due to the ultra-high risk nature of the sample, and the fact that we were interested in transition to psychosis rather than schizophrenia generally.
Previously we have shown that the volume of the left medial temporal region reduces over the transition to psychosis (Pantelis et al, 2003). Given the role of this region in verbal associative memory (Eichenbaum, 1999), and the lack of a deficit prior to psychosis onset (Brewer et al, 2006), a decline in this cognitive function would be expected. Surprisingly, no such decline was identified. One possibility is that the tests we used here are not sensitive to pathology in this brain region. Alternatively, the volumetric change identified may be too small to cause detectable differences in memory performance.
The current study is clearly limited by the small sample size; for some sub-tests there were only data for 8 participants at ultra-high risk at both time points. Furthermore, although we did not find differences between these individuals and the larger sample previously reported, it is not clear that this group is necessarily representative even of the PACE group as a whole, let alone a more general group of people who develop first-episode psychosis. Therefore we cannot be certain that the cognitive declines seen in this study would be found in all people developing psychosis. Finally, we could not control treatment, either before or after transition to psychosis. It is therefore possible that antipsychotic medication may explain the decline in the ultra-high risk with psychosis group, although most findings in early psychosis are of improvement (for example, Keefe et al, 2006). However, a very recent report has suggested that 6 weeks of treatment with risperidone can impair spatial working memory ability in early psychosis (Reilly et al, 2006).
In summary, we have demonstrated specific cognitive decline over the transition to psychosis in tasks involving efficient organisation of visual stimuli, as a result either of the illness or of its treatment. Such a decline suggests a role for visual attentional systems in the onset of the disorder.
|
|
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||